Condition: Secondary AML · Myelofibrosis · Sponsor: Aspera Biomedicines, Inc.
The purpose of this study is to test the safest and most effective dose of a new investigational drug, rebecsinib. Participants in this study will have either Secondary Acute Myeloid Leukemia (sAML) that has either returned (relapsed) or not responded to treatment (refractory) or have higher risk Myelofibrosis (MF). Participants will receive a study drug infusion on Day 1, Day 4, Day 8 and Day 11 of each 28-day cycle for a total of 6 cycles.
This description comes directly from the study's public registry record.
Curis L Scribner, MD · 510-914-8368 · cscribner@asperabio.com
Karla Mack · 443-253-0645 · kmack@asperabio.com
Always discuss trial participation with your own doctor first.
| City of Hope Center | Duarte, California, United States | Recruiting |
| UC Davis Comprehensive Cancer Center | Sacramento, California, United States | Recruiting |
| UC San Diego Moores Cancer Center | San Diego, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07250646